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Abstract
Background: According to the different sensitivity of their bone marrow CD34+ cells to in vitro treatment with
Etoposide or Mafosfamide, Acute Myeloid Leukaemia (AML) patients in apparent complete remission (CR) after
chemotherapy induction may be classified into three groups: (i) normally responsive; (ii) chemoresistant; (iii) highly
chemosensitive. This inversely correlates with in vivo CD34+ mobilization and, interestingly, also with the prognosis
of the disease: patients showing a good mobilizing activity are resistant to chemotherapy and subject to
significantly higher rates of Minimal Residual Disease (MRD) and relapse than the others. Based on its known role
in patients’ response to chemotherapy, we hypothesized an involvement of the Apoptotic Machinery (AM) in these
phenotypic features.
Methods: To investigate the molecular bases of the differential chemosensitivity of bone marrow hematopoietic
stem cells (HSC) in CR AML patients, and the relationship between chemosensitivity, mobilizing activity and relapse
rates, we analyzed their AM expression profile by performing Real Time RT-PCR of 84 AM genes in CD34+ pools
from the two extreme classes of patients (i.e., chemoresistant and highly chemosensitive), and compared them
with normal controls.
Results: The AM expression profiles of patients highlighted features that could satisfactorily explain their in vitro
chemoresponsive phenotype: specifically, in chemoresistant patients we detected up regulation of antiapoptotic
BIRC genes and down regulation of proapoptotic APAF1, FAS, FASL, TNFRSF25. Interestingly, our analysis of the AM
network showed that the dysregulated genes in these patients are characterized by high network centrality (i.e.,
high values of betweenness, closeness, radiality, stress) and high involvement in drug response.
Conclusions: AM genes represent critical nodes for the proper execution of cell death following pharmacological
induction in patients. We propose that their dysregulation (either due to inborn or de novo genomic mutations
selected by treatment) could cause a relapse in apparent CR AML patients. Based on this, AM profiling before
chemotherapy and transplantation could identify patients with a predisposing genotype to MRD and relapse:
accordingly, they should undergo a different, specifically tailored, therapeutic regimen and should be carefully
checked during the post-treatment period.
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AML is heterogeneous both at the cytogenetic and the
molecular level [1,2]. Many of these alterations have
prognostic impact on the clinical outcome, especially on
resistance to chemotherapy and relapse rates [1,2]. As
with other tumours, one of the main obstacles to suc-
cessful chemotherapy is drug resistance [3,4]. Nearly
80% of AML patients apparently achieve CR following
chemotherapy induction, however a high proportion of
them relapses and eventuallyd i e so ft h ed i s e a s e[ 5 , 6 ] .
To explain MRD or relapses in these patients after che-
motherapy, it has been suggested that the bone marrow
microenvironment may protect cancer hematopoietic
cells, allowing them to resist treatment and survive [7].
This form of resistance (called de novo drug resistance)
could be in part attributable to the interaction of the
Very Late Antigen (VLA)-4 of leukemic cells with fibro-
nectin within bone marrow stroma [8]. VLA-4 and
other adhesion molecules are involved in homing and
mobilization of hematopoietic stem cells (HSC) [9].
Treatment strategies, based on blocking adhesion mole-
cules or other proteins involved in homing, might mini-
mize MRD [10]. It has been demonstrated that patients
that are good mobilizers a r es i g n i f i c a n t l ym o r el i k e l yt o
be responsive to chemotherapy than poor mobilizers
[10]. However, unlike other leukemic patients, good
mobilizers CR AML patients are subject to significantly
higher rates of relapse than patients with lower mobili-
z a t i o nc a p a c i t y ;t h e ya l s oh a v eah i g h e rr a t eo fM R Da t
remission [11-13]. A high ability to mobilize CD34+
cells in peripheral blood (PB) was proved to be an unfa-
vourable prognostic factor, independent of others such
as class of cytogenetic risk or FAB morphotype [11-13].
It has been hypothesized that intrinsic or acquired che-
moresistance of leukemic bone marrow precursors may
be a possible explanation for the association between
high mobilization of CD34+ cells and MRD. Further-
more, it has been demonstrated that non-leukemic HSC
from AML patients show differential chemosensitivity:
this allowed the identification of three categories of
patients, characterized by: (i) normal chemosensitivity,
(ii) chemoresistance, (iii) increased chemosensitivity,
respectively (Milone et al: Chemo-sensitivity of cloni-
genic marrow precursors in AML patients in complete
remission: association with CD34+ mobilization and
with disease-free survival, submitted). A statistically sig-
nificant correlation between in vitro chemosensitivity of
CFU-GM to Etoposide and Mafosfamide, CD34+ cells
mobilization and survival was detected: patients with
high mobilization capacity showed chemoresistance of
their BFU-E and CFU-GM and lower survival rates than
patients with normal or low mobilization activity. Dysre-
gulation of the Apoptotic Machinery (AM) plays a
primary role in the response to antineoplastic therapy
[14,15]. In a previous work by some of us, it was
demonstrated that the highly interconnected nodes of
the AM network (hubs) typically represent the genes
with the highest number of genome, transcriptome and
proteome alterations in several cancer models [16].
Moreover, we found that most of AM proteins targeted
by drugs were characterized by high connectivity; in par-
ticular, there was a highly significant association
between the betweenness of these proteins and their
being targets of drugs [16]. Based on these findings and
on our data on AM involvement in anticancer treatment
(i.e., Fenretinide in neuroblastoma and Imatinib in
CML) [16], we explored the hypothesis that specific AM
expression profiles in CR AML patients may determine
the differential chemosensitivity, shown in vitro by their
bone marrow HSC. The results allow us to propose that
there is a relationship between the AM network specific
structure and its proneness to dysregulation.
Methods
The transcriptome of 84 human genes, assigned to the
Apoptotic Machinery [17], was analyzed in bone marrow
CD34+ cells from a cohort of AML patients in apparent
CR and from normal controls: in all of them, BFU-E,
CFU-E, CFU-GM hematopoietic clonogenic precursors
were checked for in vitro chemoresistance. Chemosensi-
tivity tests on freshly collected cells and molecular ana-
lysis after cell cryopreservation were performed on the
same bone marrow samples. AML patients were selected
from a cohort of 37 patients studied prospectively, in
which the HSC in vitro chemosensitivity was deter-
mined. Based on their in vitro drug sensitivity in com-
parison to normal controls, patients were divided into
three groups: (i) normally chemoresponsive, (ii) che-
moresistant, (iii) highly chemosensitive. Three patients
from the second group and three from the last one were
selected for further detailed molecular analysis.
Clinical Features of AML Patients
Patients’ clinical characteristics are reported in Addi-
tional File 1. At the time of the study, all patients were
in first apparent CR after a cycle of chemotherapy
induction and consolidation. Remission was determined
by cytogenetic analysis, cytofluorometry, immunopheno-
typing. The study was approved by the Institutional
Ethics Committee and all patients and control donors
gave their informed consent for participation in this
research.
CD34+ Cells Mobilization in PB of AML Patients
All patients were treated using a similar chemothera-
peutic regimen: one or two induction cycles with
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Page 2 of 13antracycline, cytarabine (ARA-C) and etoposide, fol-
lowed by a consolidation cycle with ARA-C and Mitox-
antrone in CR patients. A group of normal bone
marrow donors (n = 15) was also studied as control.
CD34+ mobilization was performed in all CR AML
patients after the induction phase. CR was confirmed at
that time by immunophenotyping and by cytogenetic
assessment in patients showing cytogenetic abnormal-
ities at diagnosis. CD34+ mobilization was carried out
during the recovery phase after the first consolidation
cycle: G-CSF was administered at the dose of 10 mcg/
kg/day sc, starting 10 days after the end of the consoli-
dation cycle and until the end of the aphaeretic harvest.
During mobilization, PB CD34+ cells were daily assessed
from the day in which the WBC count in the PB was >
1×1 0
9/L; the peak value of the CD34+ cells was used
as end point for evaluating the mobilizing ability.
Selection of CD34+ Cells
Mononuclear cells from bone marrow were purified on
a Ficoll gradient at the time of in vitro chemosensitivity
a s s a y s ,f r o z e ni nF B Sw i t h1 0 %D M S O ,a n ds t o r e di n
liquid nitrogen. After thawing and washing with IMDM
(containing 2% FBS) to remove DMSO, cells were incu-
bated with DNAse to degrade free DNA in solution that
would compromise separation efficiency. Separation of
CD34+ cells was performed using the CD34 MicroBead
Kit (Miltenyi Biotec Macs mini). A final cell purity
higher than 80% was achieved.
In Vitro ChemoSensitivity Assay Of Hematopoietic
Precursors
Bone marrow aspiration in AML patients was carried
out between the fourth and sixth week after the end of
CD34+ cells mobilization, during disease evaluation.
Bone marrow from normal donors was collected
through the harvest procedure for allogeneic transplan-
tation. Mononuclear cells were collected from bone
marrow samples by Ficoll density gradient separation
and divided into six aliquots of 10 million cells in
TC199. After a short incubation at 37°C, cell aliquots
were treated with increasing concentrations of Etoposide
(40 and 60 mcg/ml) or Mafosfamide (50, 75, 100, 150
mcg/ml), whereas one aliquot was left untreated as con-
trol. Cells were incubated at 37°C for 30’,w a s h e di n
cold TC199 (4°C), resuspended in IMDM with 2% FBS,
seeded (2 × 10
4/ml) in methylcellulose medium supple-
mented with erythropoietin (HSC-CFU lite with
EPO MEDIA MACS Miltenyi Biotec), and incubated in
a 37°C, 5% CO2, humidified incubator. After 14 d, the
colonies (BFU-E, CFU-E, CFU-GM) were analyzed by
inverted light microscopy. Drug sensitivity was mea-
sured by comparing the number of hematopoietic colo-
nies in samples treated with drugs to untreated controls.
Real Time PCR
Due to the very low amount of cells at the end of the
purification procedure, we had to pool CD34+ cells
from three patients with an identical chemophenotype
to perform our analysis. Total RNA was extracted by
using FastPure™ RNA Kit (Takara), according to the
Manufacturer instructions. 1 μg of total RNA was
reverse-transcribed using the High Capacity RNA-to-
cDNA Kit (Applied Biosystems). 10 ng of cDNA were
added to each well of a 96 well PCR array for quanti-
tative PCR (The Human Apoptosis RT
2 Profiler™ PCR
Array, SuperArray Bioscience Corporation, MD,
USA). The array consisted of 96 primers for 84 pro-
tein-encoding AM genes, plus five control genes
(ACTB, B2 M, GAPDH, HPRT1, RPL13A), together
with PCR and sample quality controls. PCR cycles
were performed according to the manufacturer
instructions. All experiments were performed in
duplicate. Quantitative real time PCR was performed
on a Mx3005P™ QPCR system (Stratagene, La Jolla,
CA, USA). The threshold cycle (Ct), defined as the
cycle number at which the amount of amplified target
reaches a fixed threshold, was obtained for each gene
in each sample. The Ct for each gene in each sample
was normalized to the Ct of control genes, provided
in the array, and with respect to each other (normal
vs resistant; normal vs sensitive; resistant vs sensi-
tive), according to the 2
-ΔΔCT method [17]. We also
reported our data and the corresponding fold changes
applying the following procedure (see Results): if the
2
-ΔΔCT (RQ) was ≥1 ,w eu s e dt h es a m eR Qn u m b e r
( t h ef o l dc h a n g ei sp o s i t i v e=u pr e g u l a t i o n ) ;o nt h e
other hand, if RQ was < 1, we calculated -1/RQ. In
this last case, the fold change was negative (down reg-
ulation). Analysis and visualization of data was
obtained by using the MultiExperiment Viewer 4.4
[18]. To identify differentially expressed genes for the
three different comparison reported above, we applied
a t-test between subjects (ΔCt) by using the following
parameters: assumption of equal variance; Alpha
(overall threshold p-value) = 0.05; the p-value was
based on t-distribution; the significance was deter-
mined by the Adjusted Bonferroni Correction. We
reported as up- or down regulated genes having an
expression fold change at least ≥ 2a n d≤ -2, respec-
tively. Data were partitioned through Hierarchical
Clustering, by using the Euclidean distance metric,
and the Average Linkage Clustering as linkage
method.
Network Analysis
The global AM network was generated by retrieving,
through cytoscape plug-in APID2NET [19,20], all the
available experimental interactions among all the 84 AM
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2 Pro-
filer™ PCR Array. To create the three specific AM net-
works, based on three different patient class expression
profiles, we applied on APID2NET-interaction maps the
three different expression datasets from the chemore-
sponse classes, using both colour and size gradients of
nodes to indicate expression fold changes. Analysis of
network centrality was performed by using the plug-in
Network Analyzer, which allows to retrieve all the cen-
trality parameters of a node from an established network
[21]. The degree of a node inside any biological network
mirrors the general topological features of the network,
not the real functional importance of the specific node.
For this reason, we focused our analysis also on other
centrality metrics (i.e., betweenness, closeness, radiality,
stress): in biological terms, these may be interpreted as
the probability of a protein to be functionally relevant
for other proteins and its functional ability to connect
different cell nodes. Mathematical details of these cen-
trality metrics are reported by Brandes and Erlebach
[22]. Data on functional interactions between genes and
drugs were extracted from the Comparative Toxicoge-
nomics Database (CTD), a manually curated repository
of specific chemical-gene and chemical-protein interac-
tions in vertebrates and invertebrates from published lit-
e r a t u r e[ 2 3 ] .W ei n f e r r e dt h ep o s s i b l ec o r r e l a t i o n
between dysregulation of AM genes and their network
centrality (NC) or overall drug response (ODR, esti-
mated through the number of literature citations for
drugs) by comparing the different NC and ODR in the
two different gene expression classes (differentially
expressed genes and unchanged genes) by the Wilcoxon
Rank Sum test (p-value< 0.05).
Results
In Vitro ChemoSensitivity Of Hematopoietic Precursors
In normal subjects, after incubation with maphospha-
mide at 50 mcg/mL, the mean percentage of normalized
residual growth of CFU-GM was 45% (range 24% to
57%). In AML patients, the sensitivity of CFU-GM was
highly heterogeneous: by using the values found in nor-
mal controls as cut-off points, three groups of patients
could be identified. A first group was made of 13/37
(35%) AML patients, with a sensitivity in the range of
normal controls and a mean residual CFU-GM of 33.8%
(normally chemoresponsive patients). In 6/37 patients
(16%), CFU-GM showed increased resistance with a
residual CFU-GM above the upper limit of the normal
range and a mean of 73.8% (chemoresistant patients).
The third group comprised 18/37 (48%) AML patients
with an increased sensitivity to maphosphamide, a resi-
dual growth of CFU-GM below the lower limit of the
normal range and a mean of 6.2% (highly chemosensi-
tive patients).
AM Expression Profile in CD34+ Cells from CR AML
Patients
Quantitative PCR array technology was exploited to
examine the transcript levels of 84 AM genes in CD34+
pools from CR AML patients, exhibiting a chemoresis-
tant or a chemosensitive phenotype after in vitro treat-
ment, and control donors. Transcript quantification by
the 2
-ΔΔCT method showed that 23 AM genes from the
Bcl2, Birc, Bnip, caspases, death receptors, death ligands
gene families had a nearly similar expression profile in
both classes (Tables 1 and 2; Figure 1). On the other
hand, 42 AM genes had a different expression profile in
patients from either the chemoresistant or the chemo-
sensitive class with respect to controls (Table 1; Figure
1). With the exception of BCL10, BCLAF1, DFFA, that
were up regulated, all of these AM genes were down
expressed with respect to controls (Table 1; Figure 1).
Up regulation of proapoptotic genes BCL10, BCLAF1,
DFFA and down regulation of antiapoptotic BAG3,
BIRC4, BIRC8, BNIP1, BNIP2, CARD6, CD70, CFLAR,
NOL3 in CD34+ bone marrow cells, from both che-
moresistant and chemosensitive CR patients, strongly
suggest that their AM molecular profile is prone to acti-
vation (Tables 1 and 2; Figure 1). We also found that
proapoptotic DAPK1, TNFRSF11B, TNFSF8, TP73
genes were down regulated in CD34+ cells from our
cohort of CR AML patients (Tables 1 and 2; Figure 1),
as already reported for other leukaemia patients after
chemotherapy [24-26]; we also observed a down regula-
tion of antiapoptotic BAG3, CD70, NOL3 (Tables 1 and
2; Figure 1), that had been previously reported in
patients with primary B chronic lymphocytic leukaemia
after chemotherapy [27-29]. The comparison of the AM
expression profile between resistant and sensitive sam-
ples also demonstrated the up regulation of BIRC2 and
BIRC3 (two members of the antiapoptotic BIRC family)
and down regulation of APAF1, BCL2A1, BCL2L1,
C D 4 0 L G ,C I D E B ,F A S ,F A S L ,T N F R S F 2 5 ,T N F S F 1 0i n
the former class (Tables 1 and 3; Figure 1). This expres-
sion profile would appropriately explain the in vitro
acquired chemoresistant phenotype of CD34+ cells from
high mobilizers: in fact, up regulation of BIRC genes was
already reported to be related to drug resistance in leu-
kemias and other cancers, as well as the down regula-
tion of proapoptotic APAF1, FAS, FASL, TNFRSF25
[30-34]. Contrary to data previously reported on in vivo
resistant AML cells, we detected a down regulation of
antiapoptotic BCL2A1 and BCL2L1, respectively, in
in vitro chemoresistant CD34+ cells from our cohort of
CR patients (Tables 1 and 3; Figure 1).
Specific Features of the AM Network in AML Patients
The analysis of network centrality showed that AM
genes differentially expressed in in vitro resistant CD34+
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Page 4 of 13Table 1 Expression fold changes of 84 AM genes in CD34+ cells from CR AML patients
Genes chemoresistant
vs
control
chemosensitive vs
control
chemoresistant
vs
chemosensitive
Genes chemoresistant
vs
control
chemosensitive
vs
control
chemoresistant
vs
chemosensitive
ABL1 1.05 (0.85) -1.04 (1) -1.11 (1) CASP7 -2.08 (0.14) -2 (0.03) -1.26 (0.17)
AKT1 -1.55 (0.15) -1.05 (0.87) -1.79 (0.18) CASP8 -15.74 (0.006) -19.29 (0.04) 1.01 (1)
APAF1 1.35 (0.29) 2.66 (0.08) -2.38 (0.007) CASP9 -1.95 (0.20) -1.46 (0.08) -1.61 (0.09)
BAD 1.35 (0.26) 1.47 (0.20) -1.32 (0.46) CD27 -1.49 (0.24) -2.33 (0.11) 1.29 (0.99)
BAG1 1.75 (0.34) 1.55 (0.47) -1.07 (1) CD40 -3.11 (0.02) -4.89 (0.01) 1.3 (0.50)
BAG3 -41.26 (0.0004) -76.11 (0.00009) 1.53 (1) CD40LG -16.3 (0.01) -2.57 (0.04) -7.67 (0.02)
BAG4 -2.34 (0.09) -2.99 (0.08) 1.06 (1) CD70 -10.31 (0.002) -17.03 (0.01) 1.37 (0.62)
BAK1 -1.11 (1) -1.26 (0.47) -1.06 (1) CFLAR -51.86 (0.002) -22.01 (0.003) -2.85 (0.03)
BAX 1.43 (0.80) 1.31 (0.73) -1.11 (1) CIDEA -15.74 (0.008) -19.29 (0.009) 1.01 (1)
BCL10 3.09 (0.007) 3.01 (0.007) 1.01 (1) CIDEB 1.26 (0.37) 2.55 (0.03) -2.45 (0.001)
BCL2 2.15 (0.12) 1.9 (0.23) -1.35 (0.30) CRADD -1.24 (0.18) -1.77 (0.07) 1.18 (0.52)
BCL2A1 -5.19 (0.01) -2.81 (0.02) -2.23 (0.004) DAPK1 -15.74 (0.0006) -19.29 (0.0002) 1.01 (1)
BCL2L1 -3.5 (0.007) 1.06 (0.44) -4.47 (0.005) DFFA 3.11 (0.00008) 3.01 (0.00009) 1.01 (1)
BCL2L10 -15.74 (0.01) -19.29 (0.02) 1.01 (1) FADD -5.02 (0.004) -6.41 (0.004) 1.06 (1)
BCL2L11 1.36 (0.25) 1.38 (0.26) -1.22 (0.72) FAS -7.19 (0.01) -3.53 (0.04) -2.46 (0.003)
BCL2L2 -1.25 (0.24) -1.04(1) -1.44 (0.21) FASLG -22.58 (0.005) -4.32 (0.02) -6.32 (0.01)
BCLAF1 3.12 (0.003) 3.04(0.002) 1.01 (1) GADD45A -2.09 (0.16) -2.69 (0.22) 1.06 (1)
BFAR 3.01 (0.0006) 1.84(0.03) 1.01 (1) HRK -3.75 (0.01) -6.11 (0.01) 1.35 (0.30)
BID -1.03 (0.93) 1.16 (0.43) -1.44 (0.21) IGF1R -2.29 (0.08) -3.16 (0.07) 1.14 (1)
BIK 1.1 (1) 1.47 (0.34) -1.61 (0.38) LTA -7.34 (0.05) -4.72 (0.01) -1.88 (0.12)
BIRC2 3.77 (0.006) -7.26 (0.004) 22.63 (0.001) LTBR -1.38 (0.25) -1.13 (0.47) -1.47 (0.27)
BIRC3 -3.02 (0.001) -10.13 (0.004) 2.77 (0.001) MCL1 1.51 (0.33) 1.34 (0.46) -1.07 (0.51)
BIRC4 -11.77 (0.0007) -15.14 (0.0007) 1.06 (1) NAIP 1.96 (0.13) 1.39 (0.34) 1.16 (1)
BIRC6 -1.08 (0.85) 1.04 (0.73) -1.37 (0.18) NOD1 -1.31 (0.36) -1.09 (0.94) -1.44 (0.75)
BIRC8 -17.71 (0.0005) -21.71 (0.0002) 1.01 (1) NOL3 -15.74 (0.001) -10.34 (0.0003) -1.84 (0.21)
BNIP1 -9.17 (0.0008) -10.41 (0.001) -1.06 (1) PYCARD 1.12 (0.48) 1.79 (0.07) -1.93 (0.05)
BNIP2 -8.15 (0.005) -7.52 (0.007) -1.31 (0.24) RIPK2 -1.11 (0.21) -1.69 (0.48) 1.26 (0.08)
BNIP3 -8.38 (0.02) -9.71 (0.03) -1.04 (1) TNF 2.08 (0.18) 2.3 (0.31) -1.34 (0.29)
BNIP3L -3.75 (0.02) -4.41 (0.01) -1.03 (1) TNFRSF10A -6.13 (0.013) -4.03 (0.01) -1.84 (0.13)
BRAF -1.09 (0.83) -1.27 (0.15) -1.04 (1) TNFRSF10B -5.72 (0.016) -4.92 (0.02) -1.4 (0.43)
CARD6 -15.74 (0.001) -19.29 (0.0008) 1.01 (1) TNFRSF11B -15.74 (0.007) -19.29 (0.007) 1.01 (1)
CARD8 -4.55 (0.01) -3.76 (0.01) -1.46 (0.19) TNFRSF1A 2.42 (0.13) 1.65 (0.11) 1.21 (0.76)
CASP1 -1.35 (0.45) 1.06 (0.48) -1.74 (0.01) TNFRSF21 1.1 (0.29) -1.48 (0.83) 1.35 (0.12)
CASP10 -5.12 (0.01) -6.5 (0.012) 1.05 (1) TNFRSF25 1.07 (1) 3.61 (0.03) -4.06 (0.03)
CASP14 -25.4 (0.03) -58.89 (0.0004) 1.92 (0.02) TNFRSF9 -15.74 (0.03) -18.38 (0.01) -1.04 (1)
CASP2 1.05 (1) 1.1 (1) -1.27 (1) TNFSF10 -1.25 (0.12) 1.45 (0.08) -2.2 (0.01)
CASP3 1.07 (1) -1.13 (0.68) -1.01 (1) TNFSF8 -9.04 (0.007) -10.7 (0.008) -1.02 (1)
CASP4 -1.47 (0.08) -1.57 (0.09) -1.13 (0.72) TP53 1.27 (0.20) 1.2 (0.23) -1.14 (0.70)
CASP5 -12.27 (0.002) -11.71 (0.002) -1.27 (0.16) TP53BP2 -15.74 (0.02) -19.29 (0.003) 1.01 (1)
CASP6 1.2 (0.34) 1.2 (0.43) -1.21 (0.99) TP73 -53.32 (0.006) -48.5 (0.006) -1.33 (0.70)
Fold changes of 84 AM gene expression, according to the alternative version of 2
-ΔΔCT method, for three different comparisons between phenotypic classes:
chemoresistant vs control; chemosensitive vs control; chemoresistant vs chemosensitive. When the RQ is ≥1, we reported the same RQ number (positive fold
change); when RQ is < 1, we reported -1/RQ: (negative fold change). We considered as up regulated or down regulated those genes with fold change ≥2a n d≤
-2, respectively. Genes with a fold change between 2 and -2 are considered as unchanged. Adjusted Bonferroni p-value is reported between brackets.
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Page 5 of 13Table 2 Common differentially expressed genes in chemoresistant and chemosensitive classes in comparison with
normal controls
Gene
Symbol
Category Expression NOTES
BAG3 Anti Down Down expression of BAG3 increases apoptosis induced via Bax or Fas by IL-3 deprivation in hematopoietic
cells. Furthermore, BAG3 down modulation is recently shown to enhance the apoptotic response to
chemotherapy with alkylating agents through regulation of CHK2 and CDC2 proteins in human primary
B chronic lymphocytic leukemia cells.
BCL10 Pro Up This gene contains a CARD domain, and has been shown to induce apoptosis and to activate NF-kappaB. It is
interesting that deregulation of this gene leads to pathogenesis of hematopoietic malignancy. We detected it
in HSC from our cohort of patients. Its over expression in CR CD34+ cells could be related to their proneness
to death induction.
BCL2L10 Pro Down The protein of this gene act as pro-apoptotic regulators that are involved in a wide variety of cellular activities,
interacting with other members of BCL-2 protein family including BCL2, BCL2L1/BCL-X(L), and BAX.
BCLAF1 Pro Up This gene encodes a transcriptional repressor that interacts with several members of the BCL2 family. Its
overexpression induces apoptosis.
BIRC4 Anti Down It is a protein which inhibits apoptosis through binding to tumor necrosis factor receptor-associated factors
TRAF1 and TRAF2. It also inhibits at least two members of the caspase family of cell-death proteases, caspase-3
and caspase-7.
BIRC8 Anti Down BIRC8 is involved in the control of apoptosis by direct inhibition of caspase 9.
BNIP1 Anti Down BNIP genes area members of the BCL2/adenovirus E1B 19 kd-interacting protein (BNIP) family. They interact
with the E1B 19 kDa protein which is responsible for the protection of virally-induced cell death, as well as, E1B
19 kDa-like sequences of BCL2.
BNIP2 Anti Down
BNIP3 Pro/Anti Down BNIP3 interacts with the E1B 19 kDa protein which is responsible for the protection of virally-induced cell
death, as well as E1B 19 kDa-like sequences of BCL2. The dimeric mitochondrial protein is known to induce
apoptosis, even in the presence of BCL2.
CARD6 Anti Down This protein is a microtubule-associated protein that has been shown to interact with receptor-interacting
protein kinases and positively modulate signal transduction pathways converging on activation of the inducible
transcription factor NF-kB.
CASP14 Pro Down Caspases encode members of the cysteine-aspartic acid protease (caspase) family. Sequential activation of
caspases plays a central role in the execution-phase of cell apoptosis by inducing of either TNF or FAS-
receptor.
CASP5 Pro Down
CD70 Pro Down This cytokine is also reported to play a role in regulating B-cell activation, cytotoxic function of natural killer
cells, and immunoglobulin synthesis. Its downexpression could confirm that CD34+ cells from these patients
have an expression profile prone to apoptosis and to positively respond to chemotherapy
CFLAR Anti Down c-FLIP inhibits caspase 8 activation and apoptosis mediated by death receptors, such as Fas. Furthermore,
overexpression of c-FLIP potently inhibits apoptosis induced by chemotherapy, suggesting that c-FLIP has a
role in mediating chemoresistance.
CIDEA Pro Down Cidea that has been shown to activate apoptosis by disrupting a complex consisting of DFF40/CAD.
DAPK1 Pro Down This gene commonly results over expressed in hematopoietic malignancies, but it is down regulated in
patients after chemotherapy. It could be considered a CR marker.
DFFA Pro Up DFFA is the substrate for caspase-3 and triggers DNA fragmentation during apoptosis.
NOL3 Anti Down NOL3, an apoptosis suppressor limited to terminally differentiated cells, is induced in human breast cancer and
confers chemo-and radiation-resistance.
TNFRSF11B Anti Down Downexpression of this gene in our model could be considered a CR marker: this gene commonly results over
expressed in hematopoietic malignancies, but it is down regulated in patients after chemotherapy
TNFRSF9 Anti Down This receptor contributes to the clonal expansion, survival, and development of T cells. It can also induce
proliferation in peripheral monocytes, enhance T cell apoptosis induced by TCR/CD3 triggered activation.
TNFSF8 Anti Down This gene commonly results over expressed in hematopoietic malignancies, but it is down regulated in
patients after chemotherapy. It could be considered a CR marker.
TP53BP2 Pro Down This protein is localized to the perinuclear region of the cytoplasm, and regulates apoptosis and cell growth
through interactions with other regulatory molecules including members of the p53 family.
TP73 Pro Down This gene commonly results over expressed in hematopoietic malignancies, but it is down regulated in
patients after chemotherapy. It could be considered a CR marker.
The biological functions, AM category (pro-or anti apoptotic activity), and our comments, based on our findings, are reported for each gene
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Page 6 of 13cells were positively associated to higher network central-
ity respect to unchanged genes (Wilcoxon Rank Sum
test): betweenness (p-value = 0.043), closeness (p-value =
0.019), radiality (p-value = 0.019), stress (p-value = 0.041)
(Figure 2). Moreover, these genes were more tightly asso-
ciated to drug response than unchanged genes (p-value =
0.003) (Figure 2). These network centrality parameters
are biologically more important than the simple network
degree of a node, because they demonstrate the ability of
a protein to functionally connect to and be relevant for
several others within a complex signalling network [35].
By comparing chemoresistant and chemosensitive classes,
we found that dysregulated genes are frequently critical
nodes of the AM network and drug-related genes. More-
over, by integrating the expression values of the three
profiles into the network structure, we found that the
expression modification of some nodes could lead to
important alterations of the network topology (Figure 3).
When compared to those from normal donors, the net-
works of resistant and sensitive classes appeared quite
similar; on the contrary, the direct comparison between
resistant and sensitive classes identified differences that
could unbalance the functional equilibrium of the AM
network (e.g., the down regulation of many proapoptotic
genes) (Table 3, Figure 3). These altered network struc-
tures could explain the different AM behaviour as well as
the different in vitro drug sensitivity and the clinical
phenotype of patients (i.e., MRD and relapse).
Discussion
Drug resistance is a major cause of failure in cancer
treatment [7,36]. Chemotherapy exerts on tumour cells
a strong selective pressure: accordingly, their survival
relies on a dynamic mutation process, possibly leading
to an ever fitting chemoresistance phenotype [37]. The
bone marrow microenvironment is a secluded and
potentially safe body niche, in which cancer cells can be
protected against chemotoxic agents. Mobilization from
this compartment is a complex process, that requires
the orchestrated participation of several molecules as
chemokines, adhesion molecules, and their downstream
targets [10,38]. The molecular events that regulate
HSCs’ engraftment and mobilization are still incomple-
tely defined. The precise mechanism of mobilization by
the Colony Stimulating Factors (CSF), the factor most
commonly used to mobilize hematopoietic cells from
bone marrow to PB, remains unsatisfactorily character-
ized [39,40]. CSF binding to its receptor leads to the
activation of several downstream signalling cascades
affecting cell survival, proliferation, differentiation,
migration [41]; moreover, it is well known that CSF sup-
presses apoptosis in both normal HSCs and cancer cells
[42]. In our experiments, we observed that CR patients
with high CD34+ mobilization activity showed in vitro
Figure 1 Expression matrix of AM genes in CD34+ cells from
CR AML patients. Up regulated genes are in red, down regulated
genes in green, according to the bar shown below the matrix. Each
row represents the colour coded expression of a specific gene; the
columns represent the colour coded AM profiles, obtained for
each type of comparison between classes: A = chemosensitive
patients vs controls; B = chemoresistant patients vs controls;
C = chemoresistant vs chemosensitive patients. Hierarchical
clustering of expression values is based on euclidean distances
and average linkage.
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Page 7 of 13chemoresistance of their BFU-E and CFU-GM. This was
coupled to a poorer prognosis, due to an increased
relapse rate respect to normally or highly chemosensi-
tive patients. Intriguingly, chemoresistant patients
showed an AM expression profile that strongly sug-
gested the involvement of the AM network in their
in vitro drug resistance. Thus, a relationship between
mobilization from bone marrow, apoptosis induction
and chemoresistance seems to exist in these patients.
The chemoresistant class is characterized by up regula-
tion of Birc genes (BIRC2 and BIRC3), that inhibit the
action of caspases, and down expression of proapoptotic
genes as APAF1 (an apoptosome component), FAS,
FASL, TNFRSF25, TNFSF10. This molecular phenotype
could lead to a failure in activating apoptosis in
response to chemotherapy [30-34]. It is well known that
GM-CSF inhibits Fas-induced apoptosis and stimulates
expression of BIRC family members [43,44]. This pro-
tective effect of CSF can also explain the lower complete
remission rates after chemotherapy in AML patients,
whose cells have a higher responsiveness to hematopoie-
tic viability factors in vitro [45]. Our data demonstrate a
down regulation of proapoptotic genes CD40LG,
CIDEB, TNFSF10 in chemoresistant AML patients, pre-
viously not reported in association with drug resistance.
Furthermore, differently from previous reports that
in vivo resistant AML cells express high levels of
BCL2A1 and BCL2L1 [30,34], we found that both genes
are down regulated in chemoresistant AML patients in
comparison to those from the chemosensitive class. We
suggest that this discrepancy is due to the specific fea-
tures of the different cell types analyzed: we analyzed in
vitro selected chemoresistant, possibly non-leukemic
CD34+ cells from CR AML patients, whereas Eisele
et al. and Valdez et al. studied myeloid blasts from AML
patients [46] or mononuclear cells from AML patients
[31], respectively. Why are some CR AML patients good
responders to CSF and others are not? The continued
pressure of chemotherapy may induce or select genomic
mutations, able to alter the cytokine cross-talking net-
work between cell migration and apoptosis: this would
result in an acquired drug resistance phenotype [8]. We
may otherwise assume that within the HSC population
of some CR patients, few leukemic cells survive che-
motherapy and persist under the CR threshold to be
eventually selected by the mobilizing treatment [47,48].
T h ep r e s e n c eo fas u b s t a n t i a ln u m b e ro fM R Dc e l l s
could influence the microenvironment and enhance
their protective effect from chemotherapy damage. This
would explain not only the high relapse rate, but also
the high mobilization activity through a reduced myelo-
toxicity induced by chemotherapy. Based on our results,
we suggest that the presence of MRD can lead to a
modulation of BM microenvironment that could cause
dysregulation of some components of the AM network
in HSC. Interestingly, by comparing both the resistant
and the sensitive class with control samples, we noticed
that 23 AM genes showed an expression profile
Table 3 Differentially expressed genes in chemoresistant patients respect to chemosensitive patients
Gene
Symbol
Category Expression NOTES
APAF1 pro Down It is a component of apoptosome. The apoptosome has a role in chemioresistance in pancreatic cancer.
BCL2A1 anti Down This gene is able to reduce the release of pro-apoptotic cytochrome c from mitochondria and block caspase
activation. This gene is a direct transcription target of NF-kappa B and it acts in response to cytokine TNF
and IL-1.
BCL2L1 pro/anti Down It acts as anti- or pro-apoptotic regulators. This gene is located on mitochondrial membrane and control VDAC
opening, regulating the release of cytochrome C by mitochondria.
BIRC2 anti Up This gene is a member of a family of proteins that inhibits apoptosis by binding to tumor necrosis factor
receptor-associated factors TRAF1 and TRAF2.
BIRC3 anti Up This gene is a member of a family of proteins that inhibits apoptosis by binding to tumor necrosis factor
receptor-associated factors TRAF1 and TRAF2. In cells resistant to alkylating agent, it blocks through regulation
of CHK2 and CDC2 proteins.
CD40LG pro Down It regulates B cell function by engaging CD40 on the B cell surface.
CIDEB pro Down CIDEB triggers DNA fragmentation and nuclear condensation. Its expression could be associated to resistance
to apoptosis.
FAS pro Down FAS/FASL ratio, after receiving chemotherapy, indicates chemosensitivity in several tumoral models. In addition,
the decreasing ratio during chemotherapy treatment, despite the initial values, is related to acquired
chemoresistance.
FASLG pro Down
TNFRSF25 pro Down This receptor has been shown to stimulate NF-kappa B activity and regulate cell apoptosis. The signal
transduction of this receptor is mediated by various death domains contained by adaptor proteins.
TNFSF10 pro Down This protein preferentially induces apoptosis in transformed and tumoral cells and it is expressed at a
significant level in the most of normal tissues. Its down regulation could impair the apoptosis induction.
The biological functions, AM category (pro- or anti apoptotic activity), and our comments, based on our findings, are reported for each gene.
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Page 8 of 13common to both resistant and sensitive classes and dif-
ferent respect to controls: many of these genes are
involved in an increased response to chemotherapy (e.g.,
the down regulation of BAG3, BIRC4, BIRC8, BNIP
family, CFLAR) [49,50]. Furthermore the downregula-
tion of DAPK1, TNFRSF11B, TNFSF8, TP73 could be
considered as a CR marker: these genes are commonly
over expressed in hematopoietic malignancies, but are
down regulated in patients after chemotherapy [24-26].
The detection of proapoptotic BCL10 in CR CD34+
cells, but not in normal donors (Tables 1 and 3; Figure
1), could be related to their proneness to death
induction. Dysregulationo ft h i sg e n ei sk n o w nt ob e
involved in some types of haematological malignancies
[51]. These observations suggest that non-leukemic
CD34+ cells from CR AML patients have an expression
profile apparently prone to apoptosis and to a positive
response to chemotherapy. This molecular feature satis-
factorily explains their positive response to in vivo che-
motherapy induction, leading these patients to the first
apparent CR. Plausibly, the molecular differences
observed between chemoresistant and chemosensitive
(acquired de novo mutations or residual presence of leu-
kemic cells) could be responsible for the de novo
Figure 2 Correlation among network centrality, expression and involvement in drug response. yFiles Circular Layout of the AM network
that emphasizes the nodes with high closeness and high involvement in drug response. The nodes with high overall drug response (number of
literature citations for drugs) are localized on the left half of the circle (attribute circle layout, based on number of literature citations for drugs).
The size of the nodes is related to network closeness. The colours indicate the expression fold change of AM genes (chemoresistant vs
chemosensitive), according to the bar shown below the network. The node line width indicates the number of literature citations for drugs. As
shown by red arrows, all nodes with altered expression are characterized by high closeness and involvement in drug response.
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Page 9 of 13acquired resistant phenotype, and accordingly for the
relapse. Unsurprisingly, these differentially expressed
genes are characterized by high centrality within the
AM network. Furthermore, many published data link
these genes to drug response, suggesting that they per-
form a critical role within AM signalling activated by
pharmacological treatments. Taken together these data
strongly suggest that the topology of AM network is
strictly related to its proper biological functioning. Mal-
functioning of these central nodes affects the stability of
the network and profoundly modify the physiological
cell behaviour. In agreement with other published data,
our results suggest that tumour-related defects in AM
hubs are preferentially selected [16,52]. The functional
impairment of a few nodes, which control directly or
indirectly the activities of many others in the context of
the co-occurrence of multiple genetic defects, could
represent a selective advantage during neoplastic trans-
formation and in response to pharmacological treat-
ment. The differential expression of topologically
important AM nodes in CR AML patients could ser-
iously impair the physiological equilibrium of AM.
Figure 3 Different AM network structure based on three different expression profiles. AM network structure alterations in three
different comparisons among chemoresponse classes. A = chemoresistant patients vs controls; B = chemosensitive patients vs controls;
C = chemoresistant vs chemosensitive patients. The fold changes are shown by gradients of node colours and sizes, according to the bar shown
below the networks. The use of different sizes to show the expression values underlines as different expression profiles could notably alter the
structure of a biological network: down regulated nodes have smaller sizes and, accordingly, minor molecular and functional effects on the
network; on the other hand, up regulated nodes have larger sizes and a higher potential influence on network functions.
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Page 10 of 13CD34+ cells from both classes of CR AML patients
showed AM network features that make these cells
prone to apoptosis: accordingly, it is not surprising that
these patients were in apparent CR after the first cycle
of chemotherapy induction and consolidation (Figure 3).
On the other hand, the AM network of the resistant
class showed some critical features respect to that of the
sensitive class: by impairing proapoptotic components
and activating prosurvival nodes, these differences could
reduce the ability of these cells to appropriately respond
to death stimuli (Figure 3). Some of these AM genes are
known to be dysregulated in leukaemia: up regulation of
BIRC3 and down regulation of APAF1, CIDEB, FAS,
TNFRSF25, TNFSF10 were previously identified by our
group as specific alterations of AM genes in leukemic
cells [16].
Conclusions
The ability of some cancer cell types to elude pharma-
cological apoptosis induction is apparently based on
molecular mechanisms, similar to those involved in
escaping physiological cell death. In this scenario,s o m e
AM genes represent critical nodes for the proper
response to chemotherapy. Their dysregulation in HSCs
from CR AML patients could be related to their high
mobilizing ability, in vitro chemoresistance and high
relapse rates. This molecular phenotype could result
from de novo mutations, selected by the treatment, or
be due to residual leukemic cells, positively selected by
the cytokines used for mobilization. The AM expression
profile of CD34+ cells seems to discriminate CR AML
patients from normal controls, as well as in vitro che-
moresistant CR AML patients from those who are sen-
sitive. These differences affect some critical nodes of the
AM network and could represent one of the causes of
the differential in vitro resistance of these cells. Accord-
ingly, AM profiling before chemotherapy and transplan-
tation could allow the identification of patients with a
genotype highly predisposing to relapse, in order to
treat them by different, specifically designed, therapies.
Specifically, low expression levels of APAF1, CD40LG,
CIDEB, FAS, FASL, TNFRSF25, TNFSF10 and up regu-
lation of BIRC2 and BIRC3 could pinpoint patients who
are prone to relapse. Otherwise, the characterization of
the genotype of the cells from PB could demonstrate
the characteristic molecular signature of leukemic cells
and accordingly guide the design of the therapeutic
strategy.
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